Tourette Syndrome (TS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Tourette Syndrome (TS) Emerging Therapy and TPP Insights

Thelansis's "Tourette Syndrome (TS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Tourette Syndrome (TS) Overview

Tourette syndrome (TS) is a neurodevelopmental disorder characterized by the presence of multiple motor tics and at least one vocal (phonic) tic persisting for more than one year, with onset before 18 years of age. The condition is associated with dysfunction in the cortico-striato-thalamo-cortical (CSTC) circuitry, primarily driven by dopamine dysregulation.

TS belongs to the spectrum of tic disorders, which also includes Provisional Tic Disorder and Persistent Motor or Vocal Tic Disorder. Clinically, TS follows a waxing and waning course, with symptom severity typically peaking during early adolescence.

The disorder is frequently associated with neurobehavioral comorbidities, particularly attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), significantly increasing disease burden.

Currently, there are no disease-modifying therapies for TS. Treatment is symptom-driven, with Comprehensive Behavioral Intervention for Tics (CBIT) as the first-line approach. Pharmacological therapies-including alpha-2 adrenergic agonists, dopamine antagonists, and VMAT2 inhibitors-are used in moderate-to-severe cases where tics significantly impact quality of life.

Key Highlights

• The TS patient population is predominantly pediatric, with children and adolescents accounting for the majority of diagnosed cases. In the United States, the diagnosed TS population (children and adolescents) is estimated at 159,313 in 2025, increasing to 168,631 by 2035.
• The adult diagnosed population remains significantly smaller, projected to grow from 15,815 in 2025 to 17,008 by 2035, reflecting a strong pediatric skew (~90% of total diagnosed cases).
• Diagnosed TS cases are expected to grow steadily across both pediatric and adult populations over the forecast period.
• Despite increasing diagnosis rates, a significant proportion of patients-particularly those with mild symptoms-remain undiagnosed or untreated, indicating a substantial unmet need.

Market Overview

• The Tourette syndrome treatment market was valued at $2.14 billion in 2025 (8MM) and is projected to reach $2.92 billion by 2035, growing at a CAGR of 4.1%.
• Short-term growth is expected to be stronger (6-7% CAGR through 2030), driven by pipeline advancements and improved treatment uptake.
• The pediatric population contributes the majority of revenue (65%+ share), reflecting higher diagnosis and treatment rates in younger patients.
• Overall, the TS treatment landscape is characterized by steady market expansion, driven by increasing awareness, improved diagnosis, and incremental therapeutic innovation.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Emalex Biosciences Inc.
• Noema Pharma AG
• Neurothera Labs Inc.
• Asarina Pharma